What WuXi AppTec does

WuXi AppTec Co., Ltd., founded in 2000 and headquartered in Shanghai, is a publicly listed (Shanghai 603259.SH, Hong Kong 2359.HK) global Contract Research, Development, and Manufacturing Organization (CRDMO) serving pharmaceutical and biotechnology companies across more than 30 countries. The company operates an integrated, end-to-end platform organized into three core segments: WuXi Chemistry (small molecule, oligonucleotide, peptide, and complex conjugate CRDMO services from discovery through commercial manufacturing), WuXi Biology (target discovery to candidate selection, staffed by nearly 3,000 scientists), and WuXi Testing (DMPK, toxicology, bioanalytical, and CMC services). Sub-brands such as TIDES (oligonucleotides/peptides) and WuXi STA (small molecule drug substance and drug product) extend modality coverage. Manufacturing capacity includes over 4,000 kL of small molecule API reactor volume and over 100,000 L of Solid Phase Peptide Synthesizer capacity across 20+ facilities in Asia, Europe, and North America, with a 3,452-molecule D&M pipeline (83 commercial, 91 Phase III) as of year-end 2025.

The business model is a project-based, multi-year B2B professional services model in which WuXi follows a molecule from early discovery through commercial manufacturing, generating revenue at each stage. Customers include large pharmaceutical companies (e.g., Eli Lilly, for which WuXi produces the Zepbound active ingredient), mid-size pharma, and biotech startups, with a total active customer base exceeding 6,000. WuXi and its biologics affiliate are estimated to be embedded in roughly 25% of drugs used in the United States, and approximately 65% of WuXi revenue is U.S.-derived. In FY2025 the company recorded total revenue of RMB 45.46 billion (+15.8% YoY) and adjusted non-IFRS net profit of RMB 14.96 billion (+41.3% YoY), with Q1 2026 revenue of RMB 12.44 billion (+28.8% YoY) and a backlog of RMB 59.77 billion (+23.6% YoY) as of March 2026. Quality systems are validated across FDA, EMA, NMPA, and PMDA inspections, with 741 audits and inspections passed in 2025.

A defining strategic context is the June 8, 2025 designation of WuXi AppTec by the U.S. Department of Defense under Section 1260H of the National Defense Authorization Act as a Chinese military company, which the company is contesting through a June 11, 2026 lawsuit in the U.S. District Court for the District of Columbia. The designation carries downstream implications under the BIOSECURE Act for federal procurement and existing contracts, with a five-year transition window; WuXi is responding with U.S. capacity expansion (Middletown, Delaware, online by end of 2026), continued multi-jurisdictional capacity build, and inorganic moves such as the 2026 acquisition of Dongyao Pharmaceutical.

Name

WuXi AppTec

Legal name

WuXi AppTec Co., Ltd.

Website

https://wuxiapptec.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

WuXi AppTec is a global CRDMO offering integrated pharmaceutical research, development, and manufacturing services across small molecules, oligonucleotides, peptides, and biologics, serving more than 6,000 pharma and biotech customers in 30+ countries from facilities in Asia, Europe, and North America.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA)

Keywords

• Contract research organization
• Pharmaceutical manufacturing services
• Drug development services
• Small molecule CDMO
• Biologics contract services

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. CRDMO Services Revenue: WuXi AppTec generates revenue through providing integrated Contract Research, Development and Manufacturing services. Revenue streams include chemistry services, biology services, testing services, and manufacturing services. The company operates on a project-based fee-for-service model with 'follow the molecule' strategy, generating revenue from early discovery projects that progress through development to commercial manufacturing.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

WuXi AppTec is a global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides integrated, end-to-end pharmaceutical R&D and manufacturing services. Its offerings span early drug discovery, preclinical and clinical development, testing (DMPK, toxicology, bioanalytical, CMC), and commercial-scale API and drug product manufacturing across small molecules, oligonucleotides, peptides, and biologics for pharmaceutical and biotech customers.

Product overview

WuXi AppTec is a Contract Research, Development, and Manufacturing Organization (CRDMO) that offers an integrated, end-to-end platform spanning Research (R), Development (D), and Manufacturing (M) for pharmaceutical and biotech companies. The platform is organized into three core business segments: WuXi Chemistry (small molecule, oligonucleotide, and peptide CRDMO), WuXi Biology (discovery services from target identification to candidate selection), and WuXi Testing (DMPK, toxicology, bioanalytical, and CMC testing). The TIDES CRDMO brand specifically addresses oligonucleotides and peptides. The company operates across Asia, Europe, and North America, with major U.S. facilities in San Diego, Middletown (DE), Cranbury (NJ), and Natick (MA). WuXi AppTec's model is designed to eliminate handoffs between drug development stages, enabling customers to progress molecules from early discovery through commercial manufacturing under one quality system.

Differentiator

Problem solved

Functional benefit

Brands

• WuXi Chemistry: Provides Contract Research, Development and Manufacturing Organization (CRDMO) services for new drug development from discovery to commercial, covering small molecules, oligonucleotides, peptides and complex conjugates.
• WuXi Biology
• WuXi Testing
• WuXi STA
• TIDES

Products and services

• WuXi Chemistry Provides Contract Research, Development, and Manufacturing Organization (CRDMO) services for new drug development from discovery through commercial supply, covering all synthetic molecular modalities including small molecules, oligonucleotides, peptides, and complex conjugates.
• WuXi Biology Provides a full spectrum of biology services and solutions supporting stand-alone and integrated projects, from target discovery to candidate selection and into the clinic, staffed by nearly 3,000 scientists covering all major disease areas and therapeutic modalities.
• WuXi Testing Integrated testing platform across the full life cycle of drug discovery and development, providing DMPK (drug metabolism and pharmacokinetics), toxicology, bioanalytical services, and CMC support to help customers deliver innovative medicines to patients.
• TIDES CRDMO Provides integrated discovery, development, and manufacturing services for oligonucleotides and peptides, offering the entire supply chain in one organization to address complex challenges in these rapidly growing therapeutic modalities.
• WuXi STA Small molecule drug substance (API) and drug product manufacturing services delivered at U.S. sites including San Diego, CA and Middletown, DE, under the WuXi STA brand, with FDA-inspected facilities.

Quantifiable outcome

• Revenue growth of 28.8% YoY to RMB 12.44 billion in Q1 2026
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• United Nations Global Compact (UNGC)coreOthersWuXi AppTec is a participant in the United Nations Global Compact, supporting its ten principles across human rights, labor, environment, and anti-corruption areas
• Pharmaceutical Supply Chain Initiative (PSCI)coreOthersWuXi AppTec serves as a supplier partner to PSCI, promoting responsible pharmaceutical supply chain practices
• Eli LillycoreStrategic or Co-development PartnerWuXi AppTec produces the active ingredient for Eli Lilly's obesity drug Zepbound. Approximately $30.4 billion in US revenue could be at risk during 2027 to 2030 due to Pentagon designation, with existing customers given five years to wind down contracts

Scale indicators13 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• WuXi Biologics: Sister company under WuXi group offering biologics-focused CRDMO services. Highly comparable end-to-end model for the biologics subset of WuXi AppTec's pipeline.
• Lonza Group: Swiss-headquartered global CDMO leader in small molecules, biologics, and cell & gene therapy. Closest Western competitor with comparable integrated CDMO footprint and scale.
• Catalent: U.S.-based CDMO specializing in drug product, biologics, and oral solid dose manufacturing. Direct competitor for late-stage small molecule and biologics CDMO work.
• Samsung Biologics: Korean-based biologics CDMO rapidly scaling large-scale mammalian manufacturing capacity. Competes for biologics programs WuXi wins in the global outsourcing market.
• Charles River Laboratories: U.S.-based CRO/CDMO with strong discovery, preclinical, and biologics manufacturing. Closely comparable on the discovery and testing services side of WuXi's CRDMO model.
• ICON plc: Global CRO offering clinical and laboratory services. Adjacent peer for the preclinical, bioanalytical, and central lab testing segments.

Broad incumbents

• IQVIA Holdings: Large CRO with significant R&D services business including labs, clinical, and biotech funding. Broader incumbent that overlaps with WuXi's research and discovery offerings.
• Sartorius AG: German bioprocessing equipment and services supplier. Comparable as a scaled player in the biopharma services value chain, though focused upstream on equipment and consumables.
• Thermo Fisher Scientific: Diversified life sciences giant with a PPD clinical/CRO business and extensive biopharma services. Broad incumbent serving many of the same pharma customers across multiple service lines.

Emerging players

• Eurofins Scientific: Global bioanalytical and laboratory testing services provider. Most comparable peer to WuXi Testing's DMPK, toxicology, and bioanalytical service lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/WuXi_AppTec
• LinkedInlinkedin.com/company/wuxi-apptec/posts/?feedView=all

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries6 records

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments49 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WuXi AppTec